quinazolines has been researched along with Gliosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Chopp, M; Hong, X; Jiang, F; Kalkanis, SN; Katakowski, M; Yang, H; Zhang, X; Zhang, ZG; Zheng, X | 1 |
1 trial(s) available for quinazolines and Gliosarcoma
| Article | Year |
|---|---|
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
1 other study(ies) available for quinazolines and Gliosarcoma
| Article | Year |
|---|---|
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chromones; Enzyme Inhibitors; Gene Expression; Glioma; Gliosarcoma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Morpholines; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transfection; Tyrphostins | 2007 |